Biomarker Clinical Phase Outsourcing Services Market Size

Biomarker Clinical Phase Outsourcing Services Market Size

Biomarker Clinical Phase Outsourcing Services Market size was around USD 7.9 billion in 2023 is expected to grow at over 19.2% CAGR between 2024 and 2032. High market growth can be attributed to rapid advancements in biomarker technology, increasing use of biomarkers, rising government initiatives and funding, growing emphasis on precision medicine, and globalization of clinical trials. Advancements in biomarker technologies often lead to the development of more complex and specialized assays, that can be effectively used in clinical trials.

To get key market trends

  Download Free Sample

For instance, in 2020 FDA approved the use of programmed cell death ligand-1 (PD-L1) as a biomarker for cancer treatment in a tissue-agnostic manner based on the presence of specific genetic features. Therefore, as new biomarker platforms and technologies emerge, outsourcing partners can offer expertise in adopting and optimizing these platforms for clinical trials, thereby fostering the market expansion.
 

Biomarkers in clinical phase outsourcing services refer to the use of biological indicators to support various stages of clinical trials, including study design, patient stratification, treatment response assessment, and safety monitoring. These biomarkers are utilized to provide insights into the underlying biological processes, disease mechanisms, and treatment effects, ultimately aiding in the development of novel therapeutics and personalized medicine approaches.